Can’t spell Novartis without VART: Drug study retracted for conflict of interest, data issues

A major scandal in Japan over the Novartis hypertension drug valsartan has resulted in a retraction from the Journal of Human Hypertension.  Frequent Retraction Watch subject Hiroaki Matsubara resigned his post at Kyoto Prefectural University in 2013, after his work on valsartan was shown to be riddled with data errors and undisclosed conflicts of interest. Also that year, … Continue reading Can’t spell Novartis without VART: Drug study retracted for conflict of interest, data issues

Weekend reads: Novartis fires scientist for faking data; journal accepts F-bomb-laden spam paper

The week at Retraction Watch began with a case of a South Korean engineer who had to retract ten studies at once. Here’s what was happening elsewhere, along with an update on a story we covered a few days ago:

Retraction appears for faked study of Novartis anti-cancer compound

A paper by a former postdoc at MD Anderson Cancer Center who “admitted to knowingly and intentionally falsifying” a figure has been retracted. In August, the Office of Research Integrity announced that it had sanctioned Jun Fu for faking data in a study of the results of a mouse study of NVP-HSP990, a Novartis compound designed … Continue reading Retraction appears for faked study of Novartis anti-cancer compound

MD Anderson postdoc faked results of Novartis anti-cancer compound study

A former postdoc at MD Anderson Cancer Center faked the results of a mouse study of a Novartis compound designed to fight brain tumors, according to the Office of Research Integrity (ORI). Jun Fu “admitted to knowingly and intentionally falsifying Figure 8a” in “Novel HSP90 Inhibitor NVP-HSP990 Targets Cell-Cycle Regulators to Ablate Olig2-Positive Glioma Tumor–Initiating … Continue reading MD Anderson postdoc faked results of Novartis anti-cancer compound study

Novartis Diovan scandal claims two more papers

A complicated story involving Novartis’s valsartan (Diovan) has led to the retraction of two more papers, one cascading from the other. Last September, The Lancet retracted the Jikei Heart Study after a slew of retractions of related work prompted an investigation of valsartan research. That investigation found evidence of data manipulation and the failure of … Continue reading Novartis Diovan scandal claims two more papers

Imperial clears Jatinder Ahluwalia of misconduct, blames “protracted negotiation” with Novartis for delay

Imperial College London has found that a former graduate student there — who had been found guilty of misconduct in two other institutions — did not commit fraud while at Imperial. As first reported in the Times Higher Education today:

Cryptic “legal issues” lead to retraction of paper about potential Novartis alcohol abuse drug

Readers of this blog by now know that if there’s one thing that really gets us going, it’s obfuscation. So it shouldn’t be surprising that the following retraction notice from the journal Psychopharmacology, made us particularly batty: This paper has been retracted by the author because of legal issues. The notice refers to  “Selective activation … Continue reading Cryptic “legal issues” lead to retraction of paper about potential Novartis alcohol abuse drug

Weekend reads: Self-citation farms; an editor refuses to retract; publishing enters politics

Before we present this week’s Weekend Reads, a request: Our co-founder Ivan Oransky celebrated a birthday this past week, and he’d like nothing more than a gift to Retraction Watch to support our work. Here’s your chance. The week at Retraction Watch featured a massive correction for a paper used to support the ban on Caster … Continue reading Weekend reads: Self-citation farms; an editor refuses to retract; publishing enters politics

Weekend reads: A week of whistleblower news, including what happens when one gets it wrong; questions about a widely covered study of men with guitar bags

Before we present this week’s Weekend Reads, a request: Our co-founder Ivan Oransky is celebrating a birthday this coming week, and he’d like nothing more than a gift to Retraction Watch to support our work. Here’s your chance. The week at Retraction Watch featured a psychology researcher who did the right thing; 15 retractions by … Continue reading Weekend reads: A week of whistleblower news, including what happens when one gets it wrong; questions about a widely covered study of men with guitar bags

Weekend reads: The dark side of tenure; video game-gun violence retractions; data fraud in the drug industry

Before we present this week’s Weekend Reads, a question: Do you enjoy our weekly roundup? If so, we could really use your help. Would you consider a tax-deductible donation to support Weekend Reads, and our daily work? Thanks in advance. The week at Retraction Watch featured us wondering why it takes a publisher a year and … Continue reading Weekend reads: The dark side of tenure; video game-gun violence retractions; data fraud in the drug industry